基础医学与临床 ›› 2011, Vol. 31 ›› Issue (9): 1064-1066.

• 短篇综述 • 上一篇    下一篇

低分子量周期蛋白E及其与恶性肿瘤的关系

侯建美,王旭东   

  1. 贵阳医学院
  • 收稿日期:2010-08-23 修回日期:2010-09-16 出版日期:2011-09-05 发布日期:2011-09-05
  • 通讯作者: 王旭东 E-mail:xdwang@gmc.edu.cn
  • 基金资助:
    国家自然科学基金

Low Molecular Weight Cyclin E and its Relation with Malignant Tumors

  • Received:2010-08-23 Revised:2010-09-16 Online:2011-09-05 Published:2011-09-05

摘要: 周期蛋白 E(cycli n E)与周期蛋白依赖性激酶2(cyclin-dependent kinase2, CDK2)形成活性复合物,促进细胞周期G1/S转换。正常组织和细胞主要表达全长型周期蛋白E(full-length cyclin E,FL-E),而多种肿瘤可大量表达低分子量周期蛋白E(low molecular weight cyclin E,LMW-E)。LMW-E的稳定性增加,LMW-E/CDk2激酶活性提高,引起基因组不稳定、细胞周期失调,并使乳腺癌产生内分泌治疗耐受等。LMW-E是评判乳腺癌等恶性肿瘤临床预后的重要生物标记物,也是肿瘤生物治疗极具潜力的分子药靶。

关键词: 低分子量周期蛋白E及其与恶性肿瘤的关系 , 周期蛋白E , 乳腺癌 , 低分子量 , 蛋白酶 , 细胞周期

Abstract: Cyclin E/cyclin-dependent kinase2 (CDK2) complex plays a key role in the G1/S transition of cell cycle. Full-length cyclin E (FL-E) is mainly expressed in normal tissues and cells, whereas low molecular weight cyclin E (LMW-E) can only be found in tumors. LMW-E is more stable with higher cyclin E/CDK2 kinase activity compared to FL-E, results in genomic instability and deregulation of cell cycle, and leads to endocrine resistance in breast cancer treatment. As an important biological marker of tumor prognosis, LMW-E may also be a potential target for its biological treatment.

Key words: Low Molecular Weight Cyclin E and its Relation with Malignant Tumors, Cyclin E, Breast cancer, Low molecular weight, Protease, Cell cycle

中图分类号: